CN1158261A - Chinese Patent medicine - Google Patents

Chinese Patent medicine Download PDF

Info

Publication number
CN1158261A
CN1158261A CN96120068A CN96120068A CN1158261A CN 1158261 A CN1158261 A CN 1158261A CN 96120068 A CN96120068 A CN 96120068A CN 96120068 A CN96120068 A CN 96120068A CN 1158261 A CN1158261 A CN 1158261A
Authority
CN
China
Prior art keywords
medicine
rhizoma
chinese patent
radix
patent medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN96120068A
Other languages
Chinese (zh)
Other versions
CN1057690C (en
Inventor
宁振峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN96120068A priority Critical patent/CN1057690C/en
Publication of CN1158261A publication Critical patent/CN1158261A/en
Application granted granted Critical
Publication of CN1057690C publication Critical patent/CN1057690C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

A Chinese patent medicine for curing ovary cancer with high effective rate up to 87.6% and no toxic by-effect is prepared from 16 Chinese-medicinal materials such as forsythia fruit, scrophularia root, belamcanda rhizome, burreed tuber, zedoary, etc.

Description

The Chinese patent medicine of treatment ovarian cancer
The invention belongs to a kind of oral Chinese patent medicine for the treatment of ovarian cancer.
Ovarian cancer is one of gynecological's common malignancy, and its sickness rate is about 9%, is only second to cervical cancer, occupies second of gynecological tumor.Because ovarian cancer is positioned at pelvic cavity, early discovery is difficulty relatively, in case find often to be transferred to other position, so think to threaten in the gynecological tumor maximum disease, doctor trained in Western medicine generally adopts operative therapy, but tumor and metastatic lesion be difficult to remove fully, and relapse rate is higher.And have not yet to see the report of the Chinese patent medicine of relevant treatment ovarian cancer.
The present invention aims to provide the oral Chinese patent medicine of the little treatment ovarian cancer of a kind of clinical effective rate height, side effect.
The technical scheme that realizes above-mentioned purpose is: raw material of Chinese medicine and the weight proportion of making this medicine are:
The Fructus Forsythiae 22-28a 22-28a Radix Scrophulariae 16-20a Rhizoma Belamcandae 8-12a that reins in the horse back
Rhizoma sparganic 13-17a Rhizoma Curcumae 13-17a Radix Curcumae 16-20a Rhizoma Curcumae Longae 8-12a
Stigma Croci 6-10a Cornu Saigae Tataricae 5-9a Cornu Bubali 8-12a Hirudo 5-7a
Herba Scutellariae Barbatae 16-20a Spica Prunellae 13-17a Cortex Phellodendri 13-17a Radix Angelicae Dahuricae 16-20a
(a is Unit Weight part)
The raw material of Chinese medicine of said ratio is made oral Chinese patent medicine.
Ovarian cancer is rather similar to the record of " abdomen Tan " at traditional Chinese medical science ancient books.It is relevant that routine thinks that its etiology and pathogenesis and qi depression to blood stasis, the phlegm-damp stasis of blood hinder, so always adopt vital energy regualting and blood circulation-promoting, hard masses softening and resolving to rule it by law more.It is considered herein that though the clinical symptoms domination of pathogen of ovarian cancer occurs with weakened body resistance holding concurrently mutually, evil malicious intrinsic heat, lump in the abdomen are this.Though morbidity later stage performance deficiency of both QI and blood also is because the result of pyretic toxicity damage healthy energy, therefore, we are based on traditional strengthening vital QI to eliminate pathogenic factors, and are main rule with " removing heat from blood and promoting blood circulation, clearing heat for detumescence, hard masses softening and resolving, promoting QI circulation for relieving depression ", reach the treating both the principal and secondary aspects of a disease purpose.
In this prescription with Fructus Forsythiae, Radix Curcumae, Cornu Saigae Tataricae, Cornu Bubali, Cortex Phellodendri, Rhizoma Belamcandae eliminating fire and detoxication; Rein in the horse back, Radix Scrophulariae, Rhizoma Curcumae Longae, Herba Scutellariae Barbatae, Radix Angelicae Dahuricae heat clearing away removing food stagnancy; Rhizoma sparganic, Rhizoma Curcumae, Stigma Croci, XIAZHECAO hard masses softening and resolving, the Hirudo blood circulation promoting and blood stasis dispelling.The property of medicine bitter cold of reining in the horse back in the side was usually used in removing heat from the lung and dissipating phlegm in the past clinically, treatment tracheitis and pulmonary's illness.The present invention finds that its heat clearing and blood cooling effect is very strong, has no adverse reaction again, so be used for and the said medicine compatibility, has improved curative effect greatly, and this is one of this medicine characteristic.
Be 30 routine clinical data statistics below:
30 examples mostly are the middle and advanced stage ovarian cancer patients, and wherein 21 examples were once carried out operative treatment, but the state of an illness does not still heal repeatedly.
1, criterion of therapeutical effect
Be almost recovered: the ovary carcinoma is eliminated, and clinical symptoms is improved, and pain and hemorrhage etc. stops, and can recover normal activity and work;
Take a turn for the better: clinical symptoms takes a turn for the better before the treatment to some extent, and carcinoma is basic controlling or stable;
Invalid: clinical symptoms does not have significant difference before and after the treatment.
2, curative effect statistics
The curative effect statistics that 30 routine ovarian cancer patients were taken after 2 courses of treatment of this medicine (40 days) is
Early stage late period in mid-term subtotal
Be almost recovered 164 11 (36.7%)
Take a turn for the better 393 15 (50%)
Invalid 0224 (13.3%)
Amount to 4 17 9 30
From above statistics as can be known, this group patient total effective rate reaches 86.7%, and does not all have the toxicity of discovery.
Except that ovarian cancer, this Chinese patent medicine also has better curative effect to pulmonary carcinoma, breast carcinoma, digestive tract cancer.
3, model case
Example 1: Lian Meiying, woman, 52 years old, Bei Loukou people from village, Ying County, Shanxi, first visit on October 26 in 94 year.The patient is diagnosed as ovarian cancer in JIUYUE, 94 in Datong Army Hospital, though be operative treatment, open and finds that tumor extensively shifts behind the abdomen, can't excise focus, closes the abdominal cavity then, advises the symptomatic treatment of going home.
Patient's emaciated physique when examining, deep-thready pulse, body temperature 38.6 degree, stomachache, metrorrhagia is more than, and appetite is poor, is unable to leave the bed, and gives this medicine at once, each 10 grams, every day three times is oral, advises period in a medicine to avoid with stimulating organism product such as cigarette, wine, does not avoid cold and uncooked food, symptom began to improve after the patient took medicine 10 days, and fever stops, and pain disappears, can out-of-bed activity, took medicine again 30 days, all diseases are eliminated substantially, can leave the bed and make housework, follow up a case by regular visits in May, 96, and the patient lives as usual, takes part in the work.
Example 2: Dong Shumin, woman, 36 years old, east, Tangshan City, Hebei province Luo Zhuan teacher, first visit on March 27 in 96 year.The patient defends school Affiliated Hospital in January, 96 in Tangshan Area and makes ovariectomy, because of finding in the operation that carcinoma shifts, pretend cervix uteri and gallbladder excises entirely, still sense stomachache after the patient leaves hospital, anorexia, emaciated physique, be unable to leave the bed, with beginning to take this medicine on March 28th, 96, each 10 grams, every day three times, patient's medication after 20 days symptom obviously improve, stomachache disappears, appetite increases, can begin out-of-bed activity, continue medication one month, health is normal substantially, and follow up a case by regular visits in July, 96, the patient can cycle to work, has obtained recovery from illness.
This Chinese patent medicine changes the traditional Chinese medical science to be executed the tradition of ovarian cancer and controls principle, and be main rule with " removing heat from blood and promoting blood circulation, clearing heat for detumescence; hard masses softening and resolving; promoting QI circulation for relieving depression ", and the while compatibility is reasonable, as wherein being usually used in removing heat from the lung and dissipating phlegm, the reining in the horse to be back to of treatment tracheitis and pulmonary's illness controlled ovarian cancer, cooperate with our other medicines, greatly strengthened the heat clearing and blood cooling function, have no adverse reaction again, so the clinical total effective rate of this oral Chinese patent medicine can reach 86.7%, and toxic and side effects is little.
Embodiment 1
This example adopts following Chinese medicine raw materials by weight proportion:
The Fructus Forsythiae 25a 25a Radix Scrophulariae 18a Rhizoma Belamcandae 10a that reins in the horse back
Rhizoma sparganic 15a Rhizoma Curcumae 15a Radix Curcumae 18a Rhizoma Curcumae Longae 10a
Stigma Croci 8a Cornu Saigae Tataricae 7a Cornu Bubali 10a Hirudo 6a
Herba Scutellariae Barbatae 18a Spica Prunellae 15a Cortex Phellodendri 15a Radix Angelicae Dahuricae 18a
(a is Unit Weight part)
Method for making: with above-mentioned 16 flavor medicines earlier in drying oven with the slow fire oven dry that is no more than 80 ℃, make the little Huang of Chinese medicine for degree, spread out then, choose decontamination, use the grinder pulverization, per 10 restrain medicated powder packs in the kraft paper bag, seals standby.
Instructions about how to take medicine: powder 10 grams, send down with eliminating cold for resuscitation water ante cibum, obeys 30 every day altogether and restrain, and 20 days is a course of treatment, generally medication 1-2 course of treatment.
Embodiment 2
This example adopts following Chinese medicine raw materials by weight proportion:
The Fructus Forsythiae 22a 28a Radix Scrophulariae 16a Rhizoma Belamcandae 12a that reins in the horse back
Rhizoma sparganic 13a Rhizoma Curcumae 17a Radix Curcumae 16a Rhizoma Curcumae Longae 12a
Stigma Croci 6a Cornu Saigae Tataricae 9a Cornu Bubali 8a Hirudo 7a
Herba Scutellariae Barbatae 16a Spica Prunellae 17a Cortex Phellodendri 13a Radix Angelicae Dahuricae 20a
(a is Unit Weight part)
The raw material of Chinese medicine of said ratio is made oral Chinese patent medicine.
Embodiment 3
This example adopts following Chinese medicinal raw materials:
The Fructus Forsythiae 28a 22a Radix Scrophulariae 20a Rhizoma Belamcandae 8a that reins in the horse back
Rhizoma sparganic 17a Rhizoma Curcumae 13a Radix Curcumae 20a Rhizoma Curcumae Longae 8a
Stigma Croci 10a Cornu Saigae Tataricae 5a Cornu Bubali 12a Hirudo 5a
Herba Scutellariae Barbatae 20a Spica Prunellae 13a Cortex Phellodendri 17a Radix Angelicae Dahuricae 16a
(a is Unit Weight part)
The raw material of Chinese medicine of said ratio is made oral Chinese patent medicine.

Claims (2)

1, the Chinese patent medicine of treatment ovarian cancer, it is characterized in that: raw material of Chinese medicine and the weight proportion of making this medicine are:
The Fructus Forsythiae 22-28a 22-28a Radix Scrophulariae 16-20a Rhizoma Belamcandae 8-12a that reins in the horse back
Rhizoma sparganic 13-17a Rhizoma Curcumae 13-17a Radix Curcumae 16-20a Rhizoma Curcumae Longae 8-12a
Stigma Croci 6-10a Cornu Saigae Tataricae 5-9a Cornu Bubali 8-12a Hirudo 5-7a
Herba Scutellariae Barbatae 16-20a Spica Prunellae 13-17a Cortex Phellodendri 13-17a Radix Angelicae Dahuricae 16-20a
(a is Unit Weight part)
The raw material of Chinese medicine of said ratio is made oral Chinese patent medicine.
2, Chinese patent medicine according to claim 1 is characterized in that, raw material of Chinese medicine and the weight proportion of making this medicine are:
The Fructus Forsythiae 25a 25a Radix Scrophulariae 18a Rhizoma Belamcandae 10a that reins in the horse back
Rhizoma sparganic 15a Rhizoma Curcumae 15a Radix Curcumae 18a Rhizoma Curcumae Longae 10a
Stigma Croci 8a Cornu Saigae Tataricae 7a Cornu Bubali 10a Hirudo 6a
Herba Scutellariae Barbatae 18a Spica Prunellae 15a Cortex Phellodendri 15a Radix Angelicae Dahuricae 18a
(a is Unit Weight part)
Above-mentioned Chinese medicine raw materials by weight proportion is made oral Chinese patent medicine.
CN96120068A 1996-10-18 1996-10-18 Chinese Patent medicine Expired - Fee Related CN1057690C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN96120068A CN1057690C (en) 1996-10-18 1996-10-18 Chinese Patent medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN96120068A CN1057690C (en) 1996-10-18 1996-10-18 Chinese Patent medicine

Publications (2)

Publication Number Publication Date
CN1158261A true CN1158261A (en) 1997-09-03
CN1057690C CN1057690C (en) 2000-10-25

Family

ID=5126114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96120068A Expired - Fee Related CN1057690C (en) 1996-10-18 1996-10-18 Chinese Patent medicine

Country Status (1)

Country Link
CN (1) CN1057690C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413754B2 (en) 2001-09-19 2008-08-19 Bionorica Ag Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones
CN102423369A (en) * 2011-12-29 2012-04-25 许从玉 Chinese medicinal composition for preventing or treating ovarian cancer
CN103272180A (en) * 2013-05-23 2013-09-04 王成红 Externally-applied Chinese medicine preparation for treating hysteromyoma
CN104083717A (en) * 2014-06-30 2014-10-08 韩凤娟 Traditional Chinese medicine compound composition for treating ovarian cancer and application of composition
CN106267029A (en) * 2016-10-12 2017-01-04 南宁多灵生物科技有限公司 A kind of Chinese medicine composition treating ovarian cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1083714A (en) * 1993-05-18 1994-03-16 曾纪感 A kind of cancer therapy drug of Chinese medicinal components
CN1125125A (en) * 1995-06-15 1996-06-26 何文超 Anticancer Chinese proprietary medicine and prodution method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413754B2 (en) 2001-09-19 2008-08-19 Bionorica Ag Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones
CN102423369A (en) * 2011-12-29 2012-04-25 许从玉 Chinese medicinal composition for preventing or treating ovarian cancer
CN102423369B (en) * 2011-12-29 2012-09-05 许从玉 Chinese medicinal composition for preventing or treating ovarian cancer
CN103272180A (en) * 2013-05-23 2013-09-04 王成红 Externally-applied Chinese medicine preparation for treating hysteromyoma
CN103272180B (en) * 2013-05-23 2014-07-23 王成红 Externally-applied Chinese medicine preparation for treating hysteromyoma
CN104083717A (en) * 2014-06-30 2014-10-08 韩凤娟 Traditional Chinese medicine compound composition for treating ovarian cancer and application of composition
CN106267029A (en) * 2016-10-12 2017-01-04 南宁多灵生物科技有限公司 A kind of Chinese medicine composition treating ovarian cancer

Also Published As

Publication number Publication date
CN1057690C (en) 2000-10-25

Similar Documents

Publication Publication Date Title
CN102579774B (en) Traditional Chinese medicine composition for treating tuberculosis of cervical lymph nodes
CN104248734A (en) Traditional Chinese medicine formula for treating acute gouty arthritis
CN1057690C (en) Chinese Patent medicine
CN105616805A (en) Traditional Chinese medicine preparation used for mastitis nursing and preparation method
CN1208646A (en) Medicine for treating gastrointestinal ulcer and gastritis
CN1272065C (en) Medicine for treating chronic bronchitis and bronchial asthma
CN1148214C (en) Medicine for curing bronchial asthma disease and its preparing method
CN1248727C (en) Insensitive impediment capsule and its manufacturing method
CN101757370A (en) Medication for treating thyroiditis and preparation method thereof
CN106822733B (en) Ointment for treating precancerous lesion of chronic atrophic gastritis and preparation method thereof
CN1177600C (en) Chinese medicine compound preparation for treating cervical spondylosis, and preparing process thereof
CN1183986A (en) Chinese medicine Pingguxiaociwan for curing Bi-syndrome
CN1903354A (en) Traditional Chinese medicine for treating lumbago and skelalgia
CN103705712B (en) One treats osteoporotic Chinese medicine preparation and preparation method
CN103041362A (en) Drug for treating rheumatism and rheumatoid and preparation method thereof
CN101361882B (en) Chinese medicine formulation for treating rheumatic osteoarthropathy
CN102872293A (en) Traditional Chinese medicinal powder for treating rheumatism and rheumatoid disease
CN1522743A (en) Kidney disease therapeutic pharmaceutical
CN1299727C (en) Chinese medicinal preparation for hepatitis and its preparing method (2)
CN101658549A (en) Oral medicine for treating psoriasis
CN1602905A (en) Externally applied medicine for treating hyperosteogeny and intervertebral disc protrusion and its preparation method
CN104784567B (en) A kind of pharmaceutical composition for the treatment of urinary system infection
CN1139400C (en) Medicine for treating arthritis and bone injury disease
CN1539484A (en) Vulnerary for treating fracture
CN1579434A (en) Chaihuang Tonic and its preparation method

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee